Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment

Health Technol Assess. 2002;6(2):1-89. doi: 10.3310/hta6020.

Authors

C Hyde¹, B Wake, S Bryan, P Barton, A Fry-Smith, C Davenport, F Song

Affiliation

¹ Department of Public Health and Epidemiology, University of Birmingham, UK.

PMID: 12022937
DOI: 10.3310/hta6020

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / economics
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Bone Marrow / drug effects
Bone Marrow / pathology
Cost of Illness
Cost-Benefit Analysis
Drug Resistance, Neoplasm
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / economics
Leukemia, Lymphocytic, Chronic, B-Cell / epidemiology
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Randomized Controlled Trials as Topic
Survival Analysis
Technology Assessment, Biomedical
Treatment Outcome
United Kingdom / epidemiology
Vidarabine / adverse effects
Vidarabine / analogs & derivatives
Vidarabine / economics
Vidarabine / therapeutic use*

Substances

Antineoplastic Agents
Vidarabine
fludarabine